T790M: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 27: Line 27:
{{stub}}
{{stub}}
{{No image}}
{{No image}}
__NOINDEX__

Latest revision as of 02:55, 18 March 2025

T790M is a mutation in the EGFR gene, often associated with resistance to certain cancer treatments. This mutation is most commonly found in non-small cell lung cancer (NSCLC), and is a point mutation in the DNA sequence of the EGFR gene.

Overview[edit]

The T790M mutation is a specific change in the DNA sequence of the EGFR gene, where a threonine (T) is replaced by a methionine (M) at position 790. This mutation is often associated with resistance to tyrosine kinase inhibitors (TKIs), a type of cancer treatment. The T790M mutation is most commonly found in non-small cell lung cancer (NSCLC), but can also occur in other types of cancer.

Role in Cancer[edit]

The EGFR gene is involved in regulating cell growth and division. Mutations in this gene, such as the T790M mutation, can lead to uncontrolled cell growth and the development of cancer. The T790M mutation is often associated with resistance to tyrosine kinase inhibitors (TKIs), a type of cancer treatment. This resistance occurs because the mutation changes the shape of the EGFR protein, preventing the TKIs from effectively binding to it and blocking its activity.

Detection and Treatment[edit]

The T790M mutation can be detected using a variety of methods, including DNA sequencing and polymerase chain reaction (PCR). Treatment for cancers with the T790M mutation often involves the use of third-generation tyrosine kinase inhibitors (TKIs), which are designed to overcome the resistance caused by the mutation.

See Also[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia